Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy

Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy

Abstract Background 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing less than 222 MBq 225Ac (actinium), due to limited av...

Full description

Saved in:
Bibliographic Details
Main Authors: Ho Sze Chan (Author), Erik de Blois (Author), Mark W. Konijnenberg (Author), Alfred Morgenstern (Author), Frank Bruchertseifer (Author), Jeffrey P. Norenberg (Author), Fred J. Verzijlbergen (Author), Marion de Jong (Author), Wouter A. P. Breeman (Author)
Format: Book
Published: SpringerOpen, 2016-05-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items